CRBP — Corbus Pharmaceuticals Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595097 ·
Last close
$10.69
Market Cap
$206.76M
52W High
$10.87
52W Low
$7.12
ADV30
364,359
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -36,190,000 | -35,037,000 | 126,988,000 | 23,370,000 | 24,748,000 |
| Mar 2026 | 0 | — | -24,304,000 | -22,969,000 | 144,480,000 | 25,661,000 | 18,138,000 |
| Dec 2025 | 0 | — | -21,966,000 | -20,555,000 | 168,195,000 | 28,492,000 | 20,692,000 |
| Sep 2025 | 0 | — | -24,417,000 | -23,342,000 | 109,514,000 | 26,983,000 | 17,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,668,000
Investing CF
$3,208,000
Financing CF
$77,426,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.19
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-613,436,000
Inventory
—
Receivables
—
ST Investments
$94,571,000
EBIT TTM
$-104,391,000
Pretax Income TTM
$-101,903,000
Interest Exp TTM
$0
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -85,310,000 | -78,537,000 | 168,195,000 | 20,692,000 | — | -64,491,000 |
| Dec 2024 | 0 | -48,721,000 | -40,209,000 | 155,879,000 | 13,451,000 | — | -41,794,000 |
| Dec 2023 | 0 | -45,078,000 | -44,604,000 | 28,272,000 | 35,177,000 | — | -36,100,000 |
| Dec 2022 | 0 | -34,835,445 | -42,346,903 | 66,311,940 | 33,321,923 | — | -37,544,435 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.51
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | $211.24M | $2.94 | — |
| ANTX | AN2 Therapeutics, Inc. | $212.46M | $5.63 | — |
| MSLE | Satellos Bioscience Inc. | $200.92M | $9.47 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $213.53M | $12.45 | — |
| KROS | Keros Therapeutics, Inc. | $213.74M | $10.78 | — |
News headlines (Yahoo Finance, 1h cache)
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
2026-08-06 12:00 · Yahoo
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
2026-08-04 12:30 · Yahoo
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
2026-07-28 12:00 · Yahoo
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
2026-06-01 14:04 · Yahoo
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
2026-05-21 12:00 · Yahoo
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-13 11:00 · Yahoo
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
2026-05-12 12:00 · Yahoo
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
2026-05-05 12:00 · Yahoo
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
2026-04-22 12:00 · Yahoo
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
2026-04-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.